Genentech

These novel strategies may change DME treatment paradigmThere is subset of patients with resistant or persistent DME that forms the impetus for new treatment strategies, including next-generation anti-VEGF-A and new classes of drugs. Pravin U. Dugel, MD, outlines a list of potential treatment candidates that may lead that paradigm shift.
Treat-and-extend protocol reduces burden of anti-VEGF treatment for DMEResults of the prospective TREX-DME study provide an evidence base for using a treat-and-extend protocol for administering anti-VEGF injections for eyes with diabetic macular edema.
Every New FDA Drug Approval in 2017
Every New FDA Drug Approval in 2017The last 12 drugs approved in the year, along with the other 34.
New cancer biosimilar could net major sales
New cancer biosimilar could net major salesA new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.
Subretinal therapy offers promise of lighter treatment burden for AMDRGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.
Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
FDA okays biosimilar for several cancers
FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
New treatments on the horizonEmerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.
Drug prolongs IPF life expectancy: StudyTwo recent studies demonstrate that pirfenidone (Esbriet, Genentech) prolongs life expectancy by 2.47 years for IPF patients and that Esbriet and nintedanib (Ofev, Boehringer Ingelheim) reduce the decline in lung function.
MS Group Praises New Drug Despite High Price Tag
MS Group Praises New Drug Despite High Price TagWhy a drug that costs $65,000 a year is making patient groups happy.